FOSUN PHARMA - Overseas Regulatory Announcement - Announcement in Relation to the Approval for Drug Registration of a Subsidiary

The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Approval for Drug Registration of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the

abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Chen Yuqing Chairman

Shanghai, the PRC 3 August 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

• for identification purposes only

Stock code: 600196 Stock abbreviation: Fosun Pharma No: Lin 2026-104

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval

for Drug Registration of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or

material omission, and accept legal liability for the truthfulness, accuracy and

completeness of the contents herein contained.

I. Overview

Recently, the drug registration application for Empagliflozin and Metformin Hydrochloride Sustained-release Tablets（III） (the "Drug") of Fosun Wanbang (Jiangsu)

Pharmaceutical Group Co., Ltd.* (復星萬邦（江蘇）醫藥集團有限公司), a subsidiary of

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公

司 ) (the "Company"), has been approved by the National Medical Products

Administration. The approved indication is as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus who are currently being

treated with empagliflozin and metformin hydrochloride.

II. Registration Information of the Drug

Generic Name: Empagliflozin and Metformin Hydrochloride Sustained-release Tablets（III）

Dosage Form: Tablet

Strength: empagliflozin 12.5mg and metformin hydrochloride 1,000mg

Registered Category: Chemicals Category 3

Marketing Authorization Holder/Manufacturer ： Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.* (復星萬邦（江蘇）醫藥集團有限公司)

Drug Approval Number: Guo Yao Zhun Zi H20265383

III. Research and Development of the Drug and Marketing Situation of Similar

Drugs The Drug is a chemical drug independently developed by the Group (i.e., the

Company and its subsidiaries/units, the same hereinafter). As of June 2026, the Group has

invested approximately RMB17.92 million (unaudited) in total in the research and

development of the Drug at current stage. According to the latest data of IQVIA CHPA1, the sales of Metformin Hydrochloride

and Empagliflozin Tablets in China (excluding Hong Kong, Macau and Taiwan) in 2025

was approximately RMB674 million.

IV. Impact on the Listed Company and Risk Warning This approval for marketing of the Drug will further enrich the product line of the

Group.

Due to the industry characteristics of pharmaceutical products, the specific sales

performance after the market launch of pharmaceutical products may be affected by

factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note

of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

3 August 2026

• For identification purposes only

1 Provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data cover the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.